Profound Medical Corp (PROF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,053 | -42,570 | -34,395 | -26,419 | -10,724 |
| Depreciation Amortization | 100 | 560 | 451 | 304 | 163 |
| Accounts receivable | -2,240 | -172 | -908 | 2,449 | 1,090 |
| Other Working Capital | -2,821 | -2,084 | -1,937 | 1,616 | 998 |
| Other Operating Activity | 3,431 | 6,059 | 5,148 | 23 | 190 |
| Operating Cash Flow | $-8,583 | $-38,207 | $-31,641 | $-22,027 | $-8,283 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -176 | N/A | N/A | N/A |
| Purchase Sale Intangibles | N/A | -66 | N/A | N/A | N/A |
| Other Investing Activity | 0 | -66 | 0 | 0 | 0 |
| Investing Cash Flow | $N/A | $-242 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -290 | -290 | -290 | -290 |
| Common Stock Issued | N/A | 42,444 | N/A | N/A | N/A |
| Other Financing Activity | 0 | -1,016 | 0 | 0 | 0 |
| Financing Cash Flow | $N/A | $41,138 | $-290 | $-290 | $-290 |
| Exchange Rate Effect | -845 | 2,122 | 1,845 | 2,600 | 94 |
| Beginning Cash Position | 59,723 | 54,912 | 54,912 | 54,912 | 54,912 |
| End Cash Position | 50,295 | 59,723 | 24,826 | 35,195 | 46,433 |
| Net Cash Flow | $-9,428 | $4,811 | $-30,086 | $-19,717 | $-8,479 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,583 | -38,207 | -31,641 | -22,027 | -8,283 |
| Capital Expenditure | N/A | -176 | N/A | N/A | N/A |
| Free Cash Flow | -8,583 | -38,383 | -31,641 | -22,027 | -8,283 |